Dr. Andrew P. Hansen Joins Emergent Technologies Inc

Business Wire, August 6, 2002

Business Editors & Health/Medical Writers

BIOWIRE2K

AUSTIN, Texas--(BW HealthWire)--Aug. 6, 2002

Emergent Technologies Inc. (ETI) announced today that Dr. Andrew P. ("Andy") Hansen has joined the company as vice president, New Business Development after serving as a consultant for the last year.

His responsibilities include working closely with ETI management and its portfolio companies' scientists to determine strategies for identifying potential collaborative partners who may be interested in sub-licensing the companies' intellectual property applications. His duties also include carrying out the strategies leading to contract negotiations.

"We are extremely pleased that Andy has joined ETI fulltime. His scientific and academic background in biochemistry and molecular biology coupled with his recent MBA training is an ideal fit for ETI," commented Tommy Harlan, CEO of ETI.

Born in Iowa, Dr. Hansen earned a B.S. and M.S. in Chemistry from the University of Iowa, a Ph.D. in Physical Chemistry from the University of Texas at Austin working under the supervision of Leon O. Morgan and recently an MBA from the McCombs School of Business at The University of Texas at Austin.

He has held postdoctoral positions at Michigan State University and The University of Texas and worked in basic research in the Drug Design and Development Division of Pharmaceutical Products at Abbott Laboratories. Dr. Hansen was assistant professor in the Department of Chemistry and Biochemistry and the Department of Biological Sciences at Northern Illinois University for four years where he led a research group studying the structure of proteins involved in viral infectivity.

Harlan founded ETI in 1989 and together with Rick Hodgins, ETI president, directs the activities of ETI and its four biotech companies located in Oklahoma City.

ETI is a venture capital firm that specializes in forming, funding, commercializing and managing biotech companies for the purpose of converting institutional and university-based technology into high-return ventures. Its unique process matches breakthrough technology with commercialization partners who can validate the market potential and expeditiously bring the technology to market. Investors can have confidence that risks will be reduced and the time to liquidity accelerated because ETI's process avoids unproven technologies, large front-end investments and dependency on the IPO market.

For more information, visit the ETI Web site at www.emergenttechnologies.com or contact James Ehrlich, vice president-Capital Acquisition and Investor Relations, at 512/263-3232, ext. 206 or jehrlich@emergenttechnologies.com.